Related to Gene Patenting Faces Supreme Test

• Patent Reform Battle Pits Biotech against High-Tech
  The former fears increased infringement due to lower damages under the Patent Reform Act of 2009 making its way through Congress.
  
• Intellectual Property at Crossroads
  The convergence of the patent system with the regulatory system presents complicated issues.
  
• Opinion: A Stem of Hope for Cancer Treatments
  Evidence mounts in favor of therapies targeting cancer stem cells.
  
• Customized Cancer Vaccines Finally (Maybe) Arrive
  Positive late-stage trial results are reinstating the potential of a personalized approach to treatment.
  
• Sutent—Would Biomarkers Have Helped?
  Recent failures bear out the necessity for marker development alongside drug R&D but also highlight the complexities.
  
• Potential Effects of Pending Biologics Legislation on the Patent Application Process
  While patent reform may get bumped to a later Congress, a resolution to biosimilars law may get passed as part of a healthcare reform bill.
  
• GEN Exclusive: 2009 Laskers Honor Advances in Stem Cell Technology and Cancer Therapy
  Work cited will revolutionize cancer therapy and impact a potential $700 million global stem cell market.
  
• Market Exclusivity—Paramount in Evaluating Target Companies
  The main related factors are relevant facts, freedom to operate, IP, third-party agreements, and regulatory exclusivity.
  
• Tips for Managing Bribery and Corruption Risks
  Operations in emerging markets are particularly liable.
  
• New Uncertainty Regarding Disclosure of Adverse Effects
  Recent Matrixx Initiatives decision muddies requirements set forth in Carter-Wallace over a decade ago.
  
• Cancer Cell Line Identity Crisis
  Researchers weigh in on the impact of incorrectly labeled cell lines on cancer research and drug development.
  
• Roche Takes a Stab at Getting mAbs Under the Skin
  Firm is testing Herceptin SC in Phase III and expects to couple it with a user-friendly delivery device.
  
• Antibody-Drug Conjugates to Fight Cancer
  While mAbs have been extremely successful, these empowered antibodies are touted as the next big blockbusters.
  
• Avastin: Time for a Predictive Test
  Roche’s strategy to expand the use of Avastin into the first-line and adjuvant settings is particularly dependent on identifying those most likely to see a benefit.
  
• Biomarkers Poised for Breakout Moment
  A passel of discussions at BIO highlight the importance of these disease-state indicators.
  
• Nanotechnology Enables Precise Cancer Targeting
  While first-generation nanodrugs reduced toxicity, next-gen treatments are being designed to increase efficacy.
  
• Court’s Halt of Federally Backed ESC Research May Impact Economic Growth
  If the injunction sticks, U.S. firms will likely send ESC research jobs abroad.